StockData

Johnson & Johnson vs Pfizer

JNJ and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JNJ and PFE compare

Johnson & Johnson is the larger company, worth 4.1 times as much as Pfizer ($680B against $165B).

On earnings, Pfizer is cheaper: it trades at 38.0× trailing earnings, against 42.9× for Johnson & Johnson.

Johnson & Johnson grew revenue faster over the last twelve months (7.8% versus −0.21% for Pfizer).

Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 6.8% at Pfizer.

Both pay dividends: Johnson & Johnson yields 1.9% and Pfizer 4.5%.

Johnson & Johnson scores higher on the StockData Score (12 against 9 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJNJPFE
Size and price
Market cap$680B$165B
Share price$282.55$28.89
Change, 1 year44.7%11.7%
Change, 5 years77.5%−43.1%
Beta (5Y)−0.32–
Employees138K75K
StockData Score
Total score12 (better)9
Valuation score01 (better)
Growth score3 (better)1
Performance score4 (better)2
Health score3 (better)2
Dividend score23 (better)
Valuation
P/E42.9×38.0× (better)
P/S6.8×2.6× (better)
P/B8.3×1.9× (better)
EV/EBITDA26.4×16.3× (better)
P/FCF33.0×15.0× (better)
PEG2.40–
FCF yield3.0%6.7% (better)
Fair value$150.46$18.86
Margin of safety−87.8%−53.1% (better)
Growth
Revenue growth (TTM)7.8% (better)−0.21%
Revenue growth, 5Y average2.7%8.5% (better)
Net income growth (TTM)−35.9% (better)−59.7%
EPS growth (TTM)−36.4% (better)−59.6%
EPS growth, 5Y average14.9% (better)−3.6%
Profitability
Gross margin67.6%73.2% (better)
Net margin16.2% (better)6.8%
FCF margin20.7% (better)17.2%
Return on equity20.0% (better)5.0%
Financial health
Debt / equity0.55 (better)0.74
Net debt / EBITDA1.02 (better)4.07
Current ratio1.021.27 (better)
Altman Z-score5.22 (better)2.00
Piotroski F-score46 (better)
Dividends and buybacks
Dividend yield1.9%4.5% (better)
Years of dividend growth16 (better)15
Dividend growth, 5Y average5.2% (better)2.4%
Buyback yield1.2%–
Shareholder yield3.0%4.5% (better)
Ownership
Held by institutions74.8%67.2%
Held by insiders0.04%0.03%
Insider net buying, 12 months−$154M$2.8M (better)
Superinvestors holding6 (better)2
Short interest, % of float0.71%2.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.